DEA national action plan targeting Purdue and OxyContin

The DEA national action plan targeting Purdue and OxyContin was a 2001 federal effort to address the drug’s diversion and abuse by pressing its manufacturer to change how it distributed and promoted the medication. It marked the first time the U.S. Drug Enforcement Administration had targeted a specific drug to be policed by its manufacturer, making Purdue Pharma an active part of the proposed enforcement response.

Background and Pressure

In early 2001, Art Van Zee and the Lee Coalition for Health began a petition drive asking the U.S. Food and Drug Administration to recall OxyContin. A town-hall forum Van Zee organized at the local high school in March drew 800 people, some seated in the aisles; the petition ultimately received more than 10,000 signatures, most from Lee County. The campaign reflected the scale of local concern: a Roanoke-based U.S. attorney described OxyContin as the crack of Southwest Virginia, where deaths from OxyContin overdoses had substantially surpassed those from cocaine and heroin.

The following month, the DEA developed its national action plan. The plan arose amid mounting concern over misuse and diversion, and it extended the debate beyond whether the drug should be recalled: it placed the manufacturer’s distribution and marketing practices, and the possibility of changing the drug itself, within the scope of the response.

The Plan and Purdue’s Response

The DEA asked Purdue to limit OxyContin’s distribution, rethink its marketing strategy, and consider reformulating the drug to make it abuse-resistant. The approach was historically unusual because it sought to have the company help police the particular medication whose diversion and abuse were at issue. It therefore joined federal monitoring with actions Purdue could take across its own distribution and promotion systems.

Purdue announced a ten-point plan to curb abuse. Its measures included distributing tamper-resistant prescription pads, creating an educational program to alert teenagers to the dangers of prescription drugs, and providing a $100,000 grant to establish a statewide prescription monitoring program intended to deter doctor-shopping. The company also stopped distributing its 160-milligram OxyContin pill, its most potent form, and reduced shipments to Mexico after reports that the drug was being smuggled back into the United States.

Warning and Significance

In July 2001, the U.S. Food and Drug Administration announced that it had worked with Purdue to add a black-box warning to OxyContin, the strongest type of prescription-drug caution. The warning was intended to help prevent inappropriate prescribing, misuse, and diversion. It was a subsequent regulatory step, distinct from the DEA’s April plan, but part of the same period of mounting institutional response.

The action plan’s defining significance lay in its enforcement model: rather than limiting the government’s role to policing individual users or dealers, it called on a drug manufacturer to help control distribution and address abuse. Purdue’s announced measures show how that demand translated into concrete changes and commitments, while the later black-box warning added a prominent caution to the drug’s labeling. The evidence records these interventions, but does not establish that they ended diversion or abuse.